Adalimumab for Treatment of Noninfectious Uveitis

Immunogenicity and Clinical Relevance of Measuring Serum Drug Levels and Antidrug Antibodies
Published:September 27, 2016DOI:


      To evaluate the rate of immunogenicity induced by adalimumab and its relationship with drug serum levels and clinical responses in patients with noninfectious uveitis.


      Prospective observational study.


      Consecutive patients from 1 referral center who initiated treatment with adalimumab for active noninfectious uveitis resistant to conventional therapy.


      All patients received 40 mg adalimumab every other week. Patients were evaluated clinically and immunologically before and after 4, 8, and 24 weeks of treatment.

      Main Outcome Measures

      Clinical evaluation included assessment of changes in visual acuity, degree of inflammation in the anterior chamber and vitreous cavity, central macular thickness, and retinal angiographic leakage. Immunologic evaluation included assessment of serum trough adalimumab and antibodies against adalimumab (AAA) levels and class II HLA typing.


      Twenty-five patients were enrolled. Overall, 18 of 25 patients (72%) showed a favorable clinical response to adalimumab therapy. Eleven patients (44%) achieved a complete response and 7 (28%) achieved a partial response. However, 7 of 25 patients (28%) were considered nonresponders. Median trough adalimumab serum levels were higher in responders than in nonresponders (P < 0.001). We observed AAA positivity (AAA+) at least 1 time point in 8 of 25 patients (32%), including 4 with transitory AAA and 4 with permanent AAA. In all patients with permanent AAA+, trough adalimumab levels became undetectable (P < 0.001). However, in patients who demonstrated transitory AAA+, no correlation was observed between AAA titers and adalimumab trough levels (P = 0.2).Concomitant immunosuppression did not show any protective effect on adalimumab immunogenicity in our cohort. An association between the presence of AAA+ and a worse uveitis outcome was observed only in patients with permanent AAA+, which correlated with undetectable adalimumab trough levels (P = 0.014).


      Treatment of noninfectious uveitis with adalimumab is associated with high rates of favorable clinical response. Overall, adalimumab trough levels were higher in responder patients. Development of permanent AAA was associated with undetectable trough adalimumab levels and worse uveitis outcome. Immunogenicity was more common in patients in whom uveitis was associated with a systemic disease and was not influenced by concomitant immunosuppressors.

      Abbreviations and Acronyms:

      AAA (antibody against adalimumab), AAA+ (antibody against adalimumab positivity), FA (fluorescein angiography), HLA (human leukocyte antigen), OCT (optical coherence tomography), TNF (tumor necrosis factor)
      To read this article in full you will need to make a payment


      Subscribe to Ophthalmology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Levy-Clarke G.
        • Jabs D.A.
        • Read R.W.
        • et al.
        Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders.
        Ophthalmology. 2014; 121: 785-796
        • Cordero-Coma M.
        • Sobrin L.
        Anti-tumor necrosis-α in uveitis.
        Surv Ophthalmol. 2015; 60: 575-589
        • Díaz-Llopis M.
        • Salom D.
        • Garcia-de-Vicuña C.
        • et al.
        Treatment of refractory uveítis with adalimumab: a prospective multicenter study of 131 patients.
        Ophthalmology. 2012; 119: 1575-1581
        • Yanai H.
        • Hanahuer S.B.
        Assessing response and lack of response to biological therapies in inflammatory bowel disease.
        Am J Gastroenterol. 2011; 106: 685-698
        • Bartelds G.M.
        • Krieckaert C.L.
        • Nurmohamed M.T.
        • et al.
        Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up.
        JAMA. 2011; 305: 1460-1468
        • Karmiris K.
        • Paintaud G.
        • Noman M.
        • et al.
        Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease.
        Gastroenterology. 2009; 137: 1628-1640
        • Kneepkens E.L.
        • Wei J.C.
        • Nurmohamed M.T.
        • et al.
        Immunogenicity, adalimumab levels and clinical response in ankylosing spondylitis patients during 24 weeks follow-up.
        Ann Rheum Dis. 2015; 74: 396-401
        • Menting S.P.
        • van Lümig P.P.
        • de Vries A.C.
        • et al.
        Extent and consequences of antibody formation against adalimumab in patients with psoriasis: one year follow-up.
        JAMA Dermatol. 2014; 150: 130-136
        • Vogelzang E.H.
        • Kneepkens E.L.
        • Nurmohamed M.T.
        • et al.
        Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up.
        Ann Rheum Dis. 2014; 73: 2178-2182
        • Korswagen L.A.
        • Bartelds G.M.
        • Krieckaert C.L.
        • et al.
        Venous and arterial thromboembolic events in adalimumab-treated patients with anti-adalimumab antibodies: a case series and cohort study.
        Arthritis Rheum. 2011; 4: 877-883
        • Moustou A.E.
        • Matekovits A.
        • Dessinioti C.
        • et al.
        Cutaneous side effects of anti–tumor necrosis factor biologic therapy: a clinical review.
        J Am Acad Dermatol. 2009; 61: 486-504
        • Van Schouwenburg P.A.
        • Rispens T.
        • Wolbink G.J.
        Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis.
        Nat Rev Rheumatol. 2013; 9: 164-172
        • Kriekaert C.L.M.
        • Nair S.C.
        • Nurmohamed M.T.
        • et al.
        Personalised treatment using serum drug levels of adalimumab in patients with rheumatoid arthritis: an evaluation of costs and effects.
        Ann Rheum Dis. 2015; 74: 361-368
      1. A randomized evaluation of health costs and resource utilization comparing testing-based therapy to empiric dose intensification for the management of inflammatory bowel disease. NIH Clinical Trials; NCT01960426. NIH clinical trial NCT 02065557, 2015; Accessed April 12, 2016.

        • Garcês S.
        • Antunes M.
        • Benito-Garcia E.
        • et al.
        A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies.
        Ann Rheum Dis. 2014; 73: 1138-1143
        • Roblin X.
        • Rinaudo M.
        • del Tedesco E.
        • et al.
        Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.
        Am J Gastroenterol. 2014; 109: 1250-1256
        • Jabs D.A.
        • Nussenblatt R.B.
        • Rosenbaum J.T.
        Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.
        Am J Ophthalmol. 2005; 140: 509-516
        • Nussenblatt R.B.
        • Palestine A.G.
        • Chan C.C.
        • et al.
        Standardization of vitreal inflammatory activity in intermediate and posterior uveitis.
        Ophthalmology. 1985; 92: 467-471
        • Grover S.
        • Murthy R.K.
        • Brar V.S.
        • et al.
        Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (Spectralis).
        Am J Ophthalmol. 2009; 148: 266-271
        • Sharma S.M.
        • Nestel A.R.
        • Lee R.W.
        • Dick A.D.
        Clinical review: anti-TNFalpha therapies in uveitis: perspective on 5 years of clinical experience.
        Ocul Immunol Inflamm. 2009; 17: 403-414
        • Erckens R.J.
        • Mostard R.L.
        • Wijnen P.A.
        • et al.
        Adalimumab successful in sarcoidosis patients with refractory chronic non-infectious uveitis.
        Graefes Arch Clin Exp Ophthalmol. 2012; 250: 713-720
        • Riancho-Zarrabeitia L.
        • Calvo-Río V.
        • Blanco R.
        • et al.
        Anti-TNF-α therapy in refractory uveitis associated with sarcoidosis: multicenter study of 17 patients.
        Semin Arthritis Rheum. 2015; 45: 361-368
        • Chiu Y.-L.
        • Rubin D.T.
        • Vermeire S.
        • et al.
        Serum adalimumab concentration and clinical remission in patients with Crohn's disease.
        Inflamm Bowel Dis. 2013; 19: 1112-1122
        • Menting S.P.
        • Coussens E.
        • Pouw M.F.
        • et al.
        Developing a therapeutic range of adalimumab serum concentrations in management of psoriasis: a step toward personalized treatment.
        JAMA Dermatol. 2015; 151: 616-622
        • Thomas S.S.
        • Borazan N.
        • Barroso N.
        • et al.
        Comparative immunogenicity of TNF inhibitors: impact on clinical efficacy and tolerability in the management of autoimmune diseases. A systematic review and meta-analysis.
        BioDrugs. 2015; 29: 241-258
        • Krieckaert C.L.
        • Nurmohamed M.T.
        • Wolbink G.J.
        Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner.
        Ann Rheum Dis. 2012; 71: 1914-1915
        • van den Reek J.M.
        • Pijls P.A.
        • Tummers M.
        • et al.
        Adalimumab drug survival in patients with psoriasis, Crohn's disease, and rheumatoid arthritis: relevant differences using the same treatment.
        J Am Acad Dermatol. 2016; 74: 177-179
        • van Schouwenburg P.A.
        • van de Stadt L.A.
        • de Jong R.N.
        • et al.
        Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation.
        Ann Rheum Dis. 2013; 72: 104-109
        • Billiet T.
        • Vande Casteele N.
        • Van Stappen T.
        • et al.
        Immunogenicity to infliximab is associated with DRB1.
        Gut. 2015; 64: 1344-1345
        • Steenholdt C.
        • Svenson M.
        • Bendtzen K.
        • et al.
        Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease.
        Aliment Pharmacol Ther. 2011; 34: 51-58
        • Nussenblatt R.B.
        The natural history of uveitis.
        Int Ophthalmol. 1990; 14: 303-308